NIH Fast Track Grant Awarded to Arteriocyte for Critical Limb Ischemia Research.
CLEVELAND -- Arteriocyte, a clinical stage biotechnology company announced today the receipt of a fast track Phase I/II Small Business Innovation Research Grant Award (R44HL092706-01) from National Heart, Lung, and Blood Institute National Heart, Lung, and Blood Institute,
n.pr established in 1948, this division of the National Institutes of Health is responsible for research and education on cardiovascular, pulmonary, systemic diseases, and sleep disorders. (NHLBI NHLBI,
n.pr See National Heart, Lung, and Blood Institute. ), of the National Institutes of Health (NIH). The grant award, is the first installment of the combined $2.5 million grant from the NIH to clinically evaluate the therapeutic feasibility of treating Critical Limb Ischemia with the company's expanded human umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. derived stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs (ALO212) using Arteriocyte's proprietary NANEX cell expansion technology. The company's NANEX technology provides for a rapid ex-vivo culturing of hemangioblasts, an early progenitor cell shown to have potential in improving perfusion in ischemic Ischemic
An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery.
Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation
ischemic tissues. The NIH award represents an important step in the company's commercialization of ALO212, its second stem cell pipeline product candidate, transitioning to clinical stage evaluation. The balance of the funding from the NHLBI is expected to be awarded, contingent on successful completion of the Phase I work.
The NANEX technology, developed by Dr. Hai-Quan Mao's research team at Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. , involves electrospun nanofibers that create a synthetic bone marrow "niche" environment, allowing stem cells to rapidly proliferate while maintaining their undifferentiated "stem" property. Arteriocyte is developing the NANEX platform technology for potential therapeutic use in a number of chronic and acute care settings including treatments for Critical Limb Ischemia, Compartment Syndrome, and "Blood Pharming pharming (fär`mĭng), the use of genetically altered livestock, such as cows, goats, pigs, and chickens, to produce medically useful products. " - the rapid expansion of cells for the commercial manufacture of universal donor blood.
Arteriocyte's research collaborators in the development of this technology include Dr. Christopher Cooper, (The University of Toledo National recognition
In its 125-year history UT has garnered several national accolades. The University’s programs, faculty and facilities have been highlighted in the media, including ), Drs. Vincent Pompili and Hiranmoy Das (The Ohio State University), Dr. Hai Quan Mao (The Whiting School of Engineering The G.W.C. Whiting School of Engineering, located in Baltimore, Maryland, is a highly regarded engineering school in the United States. It is located in the main Homewood campus of Johns Hopkins University in Baltimore. at Johns Hopkins University), and Dr. Amit Patel (University of Utah School of Medicine).
Arteriocyte, a clinical stage Biotechnology Company with facilities in Cleveland, Ohio and Hopkinton, Massachusetts, is developing proprietary stem cell therapies for human clinical applications. Arteriocyte's goal is to develop commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage). In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions to improve patient outcomes. Arteriocyte Medical Systems has a strategic partnership with Medtronic that includes Medtronic's cardiac surgery division distributing Arteriocyte Medical System's Magellan[TM] Autologous platelet and stem cell separation device in the Cardiac Surgery market. The Magellan system is currently in use in over 400 surgical centers worldwide.